Neural Correlates of Spatial Navigation Changes in Mild Cognitive Impairment and Alzheimer’s Disease

Abstract

Although the memory impairment is a hallmark of Alzheimer’s disease (AD), AD has also been characterized by spatial disorientation, which is present from its early stages. Spatial disorientation in AD manifests itself in getting lost in familiar and unfamiliar places and have been characterized more specifically using spatial navigation tests in both real space and virtual environments as an impairment in multiple spatial abilities, including allocentric and egocentric navigation strategies, visuo-spatial perception, or selection of relevant information for successful navigation. Patients suffering mild cognitive impairment (MCI), who are at a high risk of development of dementia, show impairment in a subset of these abilities, mainly connected with allocentric and egocentric processing. While spatial disorientation in typical AD patients probably reflects neurodegenerative changes in medial and posterior temporal, parietal, and frontal lobes, and retrosplenial cortex, the impairment of spatial navigation in MCI seem to be connected mainly with the medial temporal and also parietal brain changes. In this review, we will summarize the signs of brain disease in most MCI and AD patients showing in various tasks of spatial memory and navigation.

Procognitive effect of AC-3933 in aged mice, and synergistic effect of combination with donepezil in scopolamine-treated mice

“…Age-associated memory impairment has been shown to affect spatial and/or episodic memory (Nellessen et al, in press;Vlček and Laczó, 2014). In animal studies, the Y-maze test and the novel object test are widely used to assess test-animals immediate spatial working memory and episodic memory (i.e.…”

Cross-species translation of the Morris maze for Alzheimer’s disease

“…Patients with AD or MCI-AD are impaired in real-space, 2D, and virtual human adaptations of the Morris maze (11,12). Across species, performance in the Morris maze assay relies on hippocampal networks that are critically affected in AD (13,14).…”

Neurochemicals, Behaviours and Psychiatric Perspectives of Neurological Diseases

“…Therefore, 5-HT1A receptor provided the basis for using antagonists in AD treatment [188]. Similarly, 5-HT1B/1D was also found to be associated with cognitive dysfunction in AD.…”